Jung Kwan Jang (KGC) said on the 26th that it held an academic seminar on the theme of "latest efficacy research on red ginseng" at the International Conference on the Science of Botanicals (ICSB) in Mississippi, U.S.
According to KCG that day, about 400 attendees, including officials from key agencies such as the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH), as well as global researchers, took part in the event.
According to research presented at the conference, red ginseng showed meaningful effects across various areas, including neuroprotection and anti-aging, blood sugar control, and quality-of-life improvement. In particular, it was presented that ginsenosides, the main components of red ginseng, cross the blood-brain barrier and contribute to neuroprotection.
Results also appeared in blood sugar–related clinical studies. In a domestic study, the red ginseng intake group showed significant decreases in both postprandial and fasting blood glucose, and improvements were confirmed in key indicators such as insulin secretion. KCG noted that this is evaluated as a factor that can enhance competitiveness in the "metabolic health management" category, which has high demand in the global market.
KCG said large-scale human trials also demonstrated reduced oxidative stress and improved sleep quality.
Red ginseng products are currently expanding consumer touchpoints by entering major distribution channels such as Amazon, Costco, and Sprouts in the U.S. KCG expected particularly strong growth potential in the North American market, noting that the ingredient aligns with global health trends such as gluten-free and caffeine-free.
A KGC official said, "Red ginseng is an ingredient with scientific evidence accumulated through more than 1,200 research papers," adding, "We plan to continuously expand our market share by boosting global consumer trust through this academic conference and increasing locally tailored products."